BR112014012031A2 - derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1 - Google Patents

derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1

Info

Publication number
BR112014012031A2
BR112014012031A2 BR112014012031A BR112014012031A BR112014012031A2 BR 112014012031 A2 BR112014012031 A2 BR 112014012031A2 BR 112014012031 A BR112014012031 A BR 112014012031A BR 112014012031 A BR112014012031 A BR 112014012031A BR 112014012031 A2 BR112014012031 A2 BR 112014012031A2
Authority
BR
Brazil
Prior art keywords
parp
compounds
inhibitors
derivatives
phenyl isoquinolin
Prior art date
Application number
BR112014012031A
Other languages
English (en)
Inventor
Cirla Alessandra
Scolaro Alessandra
Zuccotto Fabio
Mariano Enrico Papeo Gianluca
D'anello Matteo
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014012031(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of BR112014012031A2 publication Critical patent/BR112014012031A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1 são providos 3-fenil-isoquinolin-1(2h)-ona, que inibem seletivamente a atividade de poli substituído (adp-ribose) polimerase de parp-1, em relação a poli (adp-ribose) polimerase de parp-2. os compostos da presente invenção são, portanto, úteis no tratamento de doenças tais como o câncer, doenças cardiovasculares, lesões do sistema nervoso central e diferentes formas de inflamação. a presente invenção também fornece métodos para a preparação destes compostos, composições farmacêuticas compreendendo estes compostos, e métodos de tratamento de doenças que utilizam as composições farmacêuticas que compreendem estes compostos.
BR112014012031A 2011-11-25 2012-11-20 derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1 BR112014012031A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190687 2011-11-25
EP12161489 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors

Publications (1)

Publication Number Publication Date
BR112014012031A2 true BR112014012031A2 (pt) 2017-05-30

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012031A BR112014012031A2 (pt) 2011-11-25 2012-11-20 derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1

Country Status (15)

Country Link
US (1) US9422243B2 (pt)
EP (1) EP2788328B1 (pt)
JP (1) JP6106182B2 (pt)
KR (1) KR20140097457A (pt)
CN (1) CN103946214B (pt)
AU (1) AU2012342562B2 (pt)
BR (1) BR112014012031A2 (pt)
CA (1) CA2856759A1 (pt)
CL (1) CL2014001323A1 (pt)
EA (1) EA027800B1 (pt)
ES (1) ES2676068T3 (pt)
HK (1) HK1200166A1 (pt)
IN (1) IN2014CN04671A (pt)
MX (1) MX2014006015A (pt)
WO (1) WO2013076090A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2611504T3 (es) 2012-03-07 2017-05-09 Institute Of Cancer Research: Royal Cancer Hospital (The) Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos
CN105722835B (zh) * 2013-09-11 2018-07-31 癌症研究协会:皇家癌症医院 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
US20180163271A1 (en) * 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
CA3001873A1 (en) 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurologicaldiseases
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664269B2 (en) * 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
JPWO2002094790A1 (ja) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
NZ537793A (en) * 2002-07-24 2007-05-31 Kyorin Seiyaku Kk 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
US8519136B2 (en) * 2008-02-22 2013-08-27 Msd K.K. Aminopyridine derivatives having aurora a selective inhibitory action
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物

Also Published As

Publication number Publication date
AU2012342562B2 (en) 2017-02-23
US20140336192A1 (en) 2014-11-13
EA027800B1 (ru) 2017-09-29
IN2014CN04671A (pt) 2015-09-18
EP2788328B1 (en) 2018-01-31
EA201491026A1 (ru) 2014-11-28
AU2012342562A1 (en) 2014-07-10
US9422243B2 (en) 2016-08-23
WO2013076090A1 (en) 2013-05-30
ES2676068T3 (es) 2018-07-16
JP2014533709A (ja) 2014-12-15
CA2856759A1 (en) 2013-05-30
KR20140097457A (ko) 2014-08-06
CN103946214A (zh) 2014-07-23
CL2014001323A1 (es) 2014-09-05
EP2788328A1 (en) 2014-10-15
CN103946214B (zh) 2016-08-17
JP6106182B2 (ja) 2017-03-29
HK1200166A1 (en) 2015-07-31
MX2014006015A (es) 2014-06-04

Similar Documents

Publication Publication Date Title
BR112015009130A2 (pt) derivados de 4-carboxamido-isoindolinona seletivos como inibidores de parp-1
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CL2015001655A1 (es) Compuestos derivados de ftalazin-1(2h)-ona, inhibidores selectivos de la poli(adp-ribosa) polimerasa-1; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
WO2011006794A8 (en) 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
BR112015006524A2 (pt) derivados de quinazolinona como inibidores de parp
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
WO2013163190A8 (en) Dna-pk inhibitors
BR112013002220A2 (pt) derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
GT201300206A (es) Imidazo(5,1-f)(1,2,4)triazinas para el tratamiento de transtornos neurológicos
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CL2011001754A1 (es) Compuestos derivados de pirido pirazina, inhibidores de poli (adp-ribosa) polimerasa (parp); composicion y combinacion farmaceutica; y uso para el tratamiento de enfermedades o condiciones tales como cancer, enfermedades cardiovasculares, metabolicas, inflamatorias y neurodegenerativas.
BR112014029851A2 (pt) composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
MX2014004861A (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
WO2013164061A8 (en) Pyrrolotriazinone derivatives
UA112795C2 (uk) Біциклічні піразинонові похідні
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
EA201171448A1 (ru) Производные изохинолин-1(2h)-она в качестве ингибиторов parp-1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.